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This paper presents the results obtained when pig anterior pituitary granule lysates are incubated with rat 
pro-opiomelanocortin (POMC). The resultant peptides were analyzed by 3 systems of high-performance 
liquid chromatography. This approach, when coupled with microsequence analysis of the conversion 
products, allowed the unambiguous identification of a major chymotryptic-like activity (pH optimum 
around 8) associated with the granule lysates with a specificity directed towards selective Tyr-X and Phe-X 
bonds within the POMC molecule. Furthermore, these results also demonstrate that although the detected 
enzyme activity gives rise to products ‘resembling’ those expected, the characterization of the ‘elusive’ 
maturation enzyme responsible for the cleavage at pairs of basic residues remains to be critically evaluated. 
Pro-opiomelanocortin Maturation enzyme Specificity Pituitary granule 
High performance liquid chromatography Microsequence 
1. INTRODUCTION 
Pro-opiomelanocortin (POMC), the pluripotent 
common precursor of ACTH, ,&endorphin, 
MSH’s and &LPH, is synthesized in the pars 
distalis, pars intermedia of the pituitary and in the 
hypothalamus of all species studied so far [l-5]. 
Sequential proteolytic cleavages of POMC convert 
the seemingly identical precursor molecules into 
tissue-specific collection of maturation products of 
varied biological activities [2,5-g]. In the anterior 
lobe of the pituitary, POMC is converted into an 
N-terminal glycopeptide (NT) [1,5,9], a joining 
peptide (JP) [6], ACTH, &LPH and to a lesser ex- 
tent into y-LPH, fl-endorphin and possibly&MSH 
[1,2,8]. In contrast, the major maturation pro- 
ducts in the pars intermedia of the pituitary require 
a possible further maturation of the N-terminal 
* To whom reprint requests should be addressed 
glycopeptide [ 10,111, the production of cu-MSH 
and CLIP from ACTH and the formation of y- 
LPH and a collection of &endorphin-like peptides 
[l-3,7,8,11]. In all cases, the sites of cleavage are 
represented by a pair of basic residues, most com- 
monly Lys-Arg or Arg-Arg [1,4,5,8-l 11. This 
signal of pairs of basic residues required for pro- 
teolytic conversion has been originally observed 
for ,d-LPH to y-LPH conversion [12], and is now 
known to be common to most pro-hormone con- 
version processes [8,13,14]. 
Recent evidence has been accumulated in favor 
of the secretory granules as being one of the major 
subcellular organelles responsible for such pair of 
basic residues cleavage. This was reported for pro- 
insulin [15] and for POMC [16,17]. Furthermore, 
post-translational modifications such as acetyla- 
tion [ 181 and amidation [ 191 were also reported to 
occur within the secretory granules. This report 
presents data obtained upon incubation of POMC 
[l, 11,201 with anterior pituitary granules and 
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unambiguous characterization of the cleavage pro- 
ducts by microsequencing. 
2. MATERIALS AND METHODS 
Reverse phase HPLC and molecular sieving 
HPLC methods used for the purification of the 
conversion products have been described [21,22]. 
tion stopped as described above. The resulting 
supernatant was applied on a G-75 superfine col- 
umn (0.9 x 100 cm) eluted with 1 M acetic acid at 
4”C, as in [21,22]. Aliquots of the resultant frac- 
tions were counted, the material under each peak 
was then repurified by reverse phase HPLC. 
Microsequencing was then performed on each 
HPLC-purified peak as described below. 
The purification of de novo biosynthetically 
[3H]Leu and [3H]Phe labeled rat pars intermedia 
Amino acid sequence analysis of radiolabeled 
peptides was performed on a Beckman 890C se- 
POMC and its in vitro maturation products ob- quenator, using 0.3 M Quadrol in the presence of 
tained after either a 1 h or a 4 h pulse labeling was 3 mg polybrene and 2.5 mg sperm whale 
achieved as in [21,22]. The identity of the in vitro apomyoglobin as carrier [9,20]. The resultant 
maturation products was confirmed by microse- thiazolinone residues at each sequenator cycle were 
quencing [1,5,8,11]. then counted in Aquasol- as in [20]. 
From 100 freshly dissected pig anterior pituitary 
lobes, the purification of the secretory granules 
(fraction P3AlO) was achieved by Percoll (Phar- 
macia) fractionation, and followed by a radioim- 
munoassay against &endorphin as in [21]. 
3. RESULTS 
3.1. Purification of pig anterior pituitary 
secretory granules 
For the pH study, secretory granules obtained 
from the Percoll fraction 10 (P3A10, see above) 
were osmotically lysed for 1 h at 37°C by incuba- 
tion with stirring of 50 ,ul P3AlO (1 mg protein) to 
which 200 ~1 various buffers were added. The buf- 
fers used were 0.1 M sodium formate (pH 3.0), 
0.1 M sodium acetate, pH 4.0,4.75, 5.0, 5.25, 5.5, 
6.0 and 7.0; 0.1 M NI&HCOj for pH 8.0, 8.5; and 
.O.l M (NH&C@ for pH 9.0. The lysed granule 
preparation was then added to an Eppendorf tube 
containing dried 20000 cpm of [‘H]Leu POMC 
[21,22] and incubation was allowed to proceed for 
5 h at 37°C. The reaction was then stopped by ad- 
ding acetic acid and guanidine/HCl (final cont. 
1 M and 1.5 M, respectively). This was then cen- 
trifuged at 100000 x ga, for 1 h to remove the Per- 
co11 and membrane components and the supernate 
was applied to the Protein Analysis HPLC col- 
umns for molecular sieving separation. 
The distributions of lysosomal @3-glucuronidase 
activity [23]), mitochondrial (monoamine oxidase 
activity [24]), protein (Bio-Rad protein assay), and 
the RNA, DNA [25] along the subcellular fractions 
and the Percoll density gradient showed that the 
ratio of &endorphin-like material over protein is 
maximal in P3AlO [21], representing a granular 
fraction with an apparent density of 1.084 g/ml. 
Some lysosomal activity was also found in this 
fraction but it did not exceed 1% of total 
lysosomal activity. 
To obtain sufficient counts for microsequence 
determination of the nature of the conversion pro- 
ducts of radiolabeled POMC by secretory granule 
lysates, two large scale incubations were perform- 
ed: 200~1 P3AlO were osmotically lysed with 
800 pl 0.1 M NI%HCOs (pH 8.0) for 1 h as 
described above. This preparation was then added 
to 1 x lo6 cpm of either [‘H]Leu or [‘HIPhe 
HPLC-purified POMC, pre-dried on a speed vat 
concentrator (Savant). The incubation was per- 
formed for 8 h, at 37°C with stirring and the reac- 
Based on the observed elution pattern on gel 
permeation HPLC [21] and by comparison with 
naturally occurring markers, it appears that the 
optimal specific conversion of POMC into 
molecules of similar size to the natural products 
occurs around pH 8. The quantitation of the 
specific conversion, defined as [cpm converted 
POMC]/[cpm unconverted POMC], is shown in 
fig.1. Although it can be seen that an important 
conversion does occur over pH 4-5, this conver- 
sion appears to be less specific than at pH 8 due to 
the formation of very small molecular weight pro- 
ducts (eluting after (r-MSH), and upon comparison 
of the elution position of the in vitro conversion 
products with that of the natural markers [21]. 
3.2. Characterization of POMC conversion 
products at pH 8 
The preparative purification by Sephadex G-75 
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Fig. 1. Calculated pH dependence of specific conversion 
of POMC by secretory granule lysates. The specific 
conversion is defined as cpm of converted POMCYCPM 
of unconverted POMC. 
superfine of [3H]Leu-labeled conversion products 
obtained at pH 8.0 is shown in fig.2 (upper panel). 
This allowed the separation of 7 peaks (denoted IL 
to VIIL). The material under each peak was pooled 
and repurified by reverse phase HPLC in 
HFBA/n-propanol system [21] as shown in the 
lower panel of fig.2: the elution position of the 
natural marker peptides of similar size is also 
shown (fig.2). The material under each peak which 
appeared to coelute with the rat marker peptides, 
was subsequently repurified in the TFA/n- 
propanol system [21]. In this system, apparent 
coelution with the rat marker similarly sized 
molecules also occurred, thereby providing the 
source of peptides used for microsequence 
determination. 
From fig.2, it can be seen that incubation of rat 
POMC with pig anterior pituitary granule lysates 
at pH 8, results in conversion products eluting 
close to the position of in vitro rat POMC matura- 
tion products. These include the NT-ACTH, NT- 
JP, &LPH and y-LPH marker peptides (fig.2, 
middle and lower panels, peaks 2, 3, 5, 6, 8). 
However, no peak appeared to coelute with ,& 
endorphin. Moreover, it can be noticed that peak 
5 elutes slightly later than authentic rat @-LPH 
marker (fig.2, panel IVL). 
An identical approach was also used for the 
purification of [3H]Phe-labeled POMC conversion 
products, and gave similar results (not shown). 
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Fig.2. Upper panel: Preparative Sephadex G-75 
superfine chromatography of cleavage products 
obtained following incubation of lo6 cpm of 13H]Leu 
POMC with P3AlO at pH 8.0 (section 2). The 7 peaks 
resolved are denoted IL-VIIL, where the subscript L 
denotes [3H]Leu-labeled peptides. The fraction size is 
1 ml, and an aliquot of 10 pl was counted. Lower panel: 
The repurification of peaks IL-VIIL by reverse-phase 
HPLC using a 5 /rM ODS column eluted using the 
HFBA/n-propanol system [21]. The elution positions of 
rat marker peptides are shown here for comparative 
purposes. The material under peaks l-8 was repurified 
using the same column by reverse-phase HPLC using the 
TFA/n-propanol system [21], before microsequence 
determination. The size of each fraction is 0.5 ml and an 
aliquot of 25 pl was counted. 
This provided [3H]Phe-labeled conversion pro- 
ducts for further confirmation of the microse- 
quence identification of the nature of peptides 4, 6 
and 7 (fig.2, table 1). 
3.3. Microsequence identification of POMC 
conversion products 
Table 1 and fig.3 summarize the [‘H]Leu and 
[3H]Phe microsequence data of the peptides under 
peaks 1-8 defined in fig.2. The [3H]Leu amino 
acid sequence of peptides 1,2 and 3 clearly showed 
3,11,17,18 
3,11,17,18 
3,11,17,18 
4,12,16 
4,12,16 
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Table 1 
Microsequence results of [3H]Leu- and [“HIPhe-labeled peptides l-8 (see fig.4, middle and lower panels) 
Peak 
no. 
Sequence positions 
[3H]Leu [3H]Phe 
Peptide starts from Probable Probable 
POMC residue no. identification cleavage site 
$10 
5 
14 
1 
1 
1 
52 
137 
100 (or) 164 
169 
137 
POMC (I-209) 
POMC (1-136) 
POMC (l-99) 
POMC (52- ) 
POMC (137-209) 
POMC (100-136) 
or (164- ) 
POMC (169-209) 
POMC (137-168) 
136 1 137 
Phe-Lys 
99 11oo 
Tyr-Ser 
52 1 52 
Tyr-Val 
136 1 137 
Phe-Lys 
99 &loo 
Tyr-Ser 
1630r164 
TyriArg 
168J 169 
Phe-Arg 
136 1 137 
Phe-Lys 
The identification of the peptides and the deduction of the cleavage site is also shown, based on the nucleotide [27] 
and protein [20,26,28] sequences of rat POMC and related peptides. The numbers in parentheses represent he residue 
positions along the proposed protein sequence [27]. No Leu could be detected uring the first 20 cycles in the sequence 
of peptides 4, 6 and 7. For peptides 4 and 6, the (52- ) and (164- ) mean that no carboxy-terminal identification 
could be deduced, although these peptides start at residues 52 and 164 of POMC, respectively 
that they contain the NHz-terminal segment of 
POMC, since leucine appears at residues 3, 11, 17 
and 18 [26-281 (fig.3). These results taken together 
with the app. i&values on Sephadex G-75 super- 
fine (fig.2, upper panel), and their elution position 
on reverse phase HPLC in either HFBA/n- 
propanol or TFA/n-propanol of these peptides, 
allowed their identification as authentic un- 
converted POMC for peak 1 (residues l-209 of 
POMC, fig.3); NT-ACTH for peak 2 (POMC 
residues 1-136); and NT-JP-like for peak 3 
(POMC residues l-99). 
Table 1 also shows that peptides 5 and 8 contain 
leucine at residues 4, 12 and 16. Based on the 
known leucine sequence of rat ,&LPH, y-LPH and 
POMC [20,26-281, it is clear that these two pep- 
tides contain the NHz-terminal sequence of either 
,&LPH or y-LPH plus two residues (since the 
natural form of these peptides contain leucine at 
positions 2, 10 and 14; fig.3). From the reported 
DNA sequence of rat POMC [27] and the elution 
position of these peptides on either HPLC or 
Sephadex G-75, it can be inferred that peak 5 
represents Lys-Arg-,&LPH (POMC residues 
137-209; see fig.3). Using the above arguments, 
added to the fact that no ,&endorphin-like material 
was observed, peak 8 was identified as a 
Lys-Arg-y-LPH related peptide. Both of these 
peptides imply a PheLLys cleavage of POMC to 
produce them (cleavage between residues 136- 137 
of POMC; fig.3). Furthermore, the finding of 
phenylalanine at position 14 in peak 7 (table 1) sug- 
gests that this peptide could start either from posi- 
tion 168 or from position 183 of POMC (fig.f), 
both indicating a PheLX cleavage. However, the 
absence of leucine in the first 20 residues (present 
at positions 14 and 17 of Bendorphin) clearly 
points out the position 169 in POMC as the most 
probable starting position for peptide 7. This 
assertion is reinforced by the elution of this peptide 
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61 75 95 99 100 104 105 120 
. . . . . . . . . . . Gin Arq-Arq Ala 
El 
. . . . . . . . . . . . . . . . . Ssr-lyr~SeSer-Het-Glu-His Arq . . . . . . . . . . 
I I ACIH 
(98-136) 
121 115 136 140 14R 152 165 170 180 
y-LPH 
(139-176) 
8-LPH 
(139-209) 
181 182 196 209 
t . . . . . me . . . . . Gin-COnH 
E-f:H) 
(179-209) 
I 
Fig.3. Schematic representation of rat POMC sequence [27] and the peptide bonds cleaved at pH 8.0 by pig secretory 
granule lysates. The pairs of basic residues expected to be cleaved in vivo are boxed in rectangles. The circles represent 
the leucine and phenylalanine residues positioned by microsequence of peptides l-8 (fig.2, table 1). The full arrows 
represent he unambiguously deduced cleavage sites based on the microsequence results. The dashed arrows represent 
the two possible cleavage sites inferred from the sequence of [“HIPhe-labeled peptide 6 (section 3, table 1). The 
definition of the 74, 19, 39, 38 and 71 residues N-terminal glycopeptide (NT), joining peptide (JP), adrenocorticotropin 
(ACTH), y-lipotropin (y-LPH), &endorphin @-END) and &lipotropin (&LPH), respectively, is depicted below the 
POMC sequence. 
in peak VL on Sephadex G-75, thus indicating an 
Mr slightly greater than that of ,&endorphin. 
Taken together, it is proposed that peak 8 is a 
shorter Lys-Arg-y-LPH-like peptide ending at 
residue 168 (i.e., POMC residues 137-168), while 
peak 7 represents an N-terminally extended /?- 
endorphin-like peptide starting at residue 169 (i.e., 
POMC residue 169-209). This result implies a 
PheLArg cleavage site (between residues 168-169 
of POMC). 
Finally, two other minor peptides were iden- 
tified (table l), one of them (peptide 4) as a y- 
MSH-like peptide produced via a TyrLVal 
cleavage, thereby starting at residue 52 of the 
POMC sequence, and the second (peptide 6) either 
as a shorter ACTH-like peptide starting at residue 
100 (POMC residues lOO-136), or a ,&MSH-like 
fragment starting at residue 164. Nevertheless, 
both possibilities clearly indicate a TyrLX cleavage 
site, either a TyrLSer or a TyrLArg cleavage, 
respectively. 
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4. DISCUSSION 
Pulse and pulse-chase experiments together 
with subcellular fractionation techniques have 
shown that the cleavage of precursor molecules at 
pairs of basic residues eems to be localized within 
the secretory granules (maturation processes 
reviewed in [ 131). However, very little information 
pertaining to the nature of the enzyme(s) involved 
in such an important cellular processing step is yet 
available. Two schools of thought have been 
brought forward. On the one hand, results obtain- 
ed with pro-insulin and pro-glucagon [15,29], and 
with POMC [16,17], have shown that the enzyme 
involved is an arginyl thiol protease-like with an 
acidic pH optimum around pH 5. On the other 
hand, data obtained on secretory granules prepara- 
tions using ,&LPH as a substrate, also have shown 
that the enzyme invoIved is possibly a serine pro- 
tease with a basic pH optimum around pH 8 
[30-321. Although an intragranular pH of S-6 has 
been reported [33], this does not necessarily mean 
that the pH optimum for the maturation enzyme 
should be coincident. 
In this report, it was shown that a pH study by 
molecular sieving HPLC of the conversion activity 
observed in porcine anterior pituitary granule 
lysates using rat POMC as a substrate (pH 8.0) was 
optimal for cleavage into products imilarly sized 
to known maturation products (fig.1) [21]. At pH 
5, although some conversion does occur, yet it 
does not seem to yield similarly sized products as 
natural markers in this chromatographic system 
using denaturing eluants 1211. 
The major type of cleavage observed at pH 8.0 
is shown to be directed towards either Phe-X or 
Tyr-X bonds. This suggests a chymotryptic-like 
proteolytic activity. Hence, the major enzymatic 
activity one observes with secretory granule 
preparations at pH 8.0 is not that of the sought 
maturation enzyme(s), since pairs of basic residues 
cIeavage did not occur in significant amounts. 
Although electron microscopy of fraction P3A10 
showed an enrichment in granules (not shown), 
contamination by other organelles is not unex- 
pected. Indeed, due to the presence of some 
lysosomes in P3AlO (c 1 Yo), it cannot be excluded 
that the proteolytic activity observed at pH 8 could 
be the result of a highly active lysosomal 
contaminant, 
These results clearly point out the pitfalls and 
limitations of subcellular f actionation for obtain- 
ing sufficiently pure secretory granules. This is 
especially more pronounced when an enzymatic ac- 
tivity is sought which could well be masked by 
another major cont~inati~ activity; e.g., the 
ch~otr~tic-like enzyme reported here. 
In conclusion, the approach used for conversion 
product characterization coupled with a further 
purification of the granule lysates preparation 
should lead to a more realistic procedure for the 
systematic search of pro-hormone mat~ation en- 
zyme(s). Furthermore, the results reported in the 
literature concerning the nature of the converting 
enzyme present in secretory granules preparations 
should be seriously and critically evaluated in the 
light of the present results, and the products 
carefully checked by ~crosequencing. 
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